Hong Kong Breast Cancer Therapeutics Market Report 2022 to 2030

Hong Kong Breast Cancer Therapeutics Market Analysis

$ 3999

The growing prevalence and recent technological advancements in Hong Kong are responsible for the market growth from $29 Mn in 2022 to $83 Mn with a CAGR of 13.9% for the year 2022-2030. The Hong Kong breast cancer therapeutics market is segmented by therapy, cancer type, and by distribution channel. Lee's Pharmaceutical Holdings Ltd, Bristol-Myers Squibb Co., and Eli Lilly and Co. are major companies in the Hong Kong breast cancer therapeutics market.

ID: IN10HKPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Hong Kong AUTHOR: Parul Choudhary

Buy Now

Hong Kong Breast Cancer Therapeutics Market Executive Analysis

The Hong Kong breast cancer therapeutics market size is at around $29 Mn in 2022 and is projected to reach $83 Mn in 2030, exhibiting a CAGR of 13.9% during the forecast period. In Hong Kong, 15.9% of all government recurrent spending, or $14.8 Bn, was designated to cover ongoing healthcare costs in the fiscal year 2021–2022. Accelerating the replacement or purchase of medical equipment, introducing cutting-edge medical gadgets, and promoting primary healthcare services are additional resources allocated to improving government medical services. For the Hospital Authority's benefit, Hong Kong has begun two concurrent 10-year hospital development plans, totaling $64 Bn. These plans will allow for the expansion and modernization of healthcare facilities. The first 10-year plan will be finished by 2027 and is expected to cost $25.6 Bn USD.

In Hong Kong, breast cancer is the most prevalent kind of cancer in women. 4 761 new cases of breast cancer were reported in 2019, making up 27.4% of all new cancer cases among women in Hong Kong. At diagnosis, the median age was 58. The annual incidence rate was 117 per 100 000 women on a crude basis. In Hong Kong, breast cancer ranked third among the cancers that claimed the lives of females. This malignancy claimed the lives of 852 women in total in 2019 or 13.7% of all female cancer deaths.

Around 29%-58% of the women surveyed in Hong Kong had never heard of mammography (MMG). Women who regularly perform Breast Self-examination (BSE), Clinical Breast Examination (CBE), and MMG had respective prevalence rates of 29%–33.3%, 37.8%–44.0%, and 18.0%–32.7%. In Hong Kong, there is no comprehensive breast cancer screening program. Local recommendations for breast cancer screening and prevention are created by the Cancer Expert Working Group on Cancer Prevention and Screening. Women categorized as having a high or moderate risk of developing breast cancer were advised to have an MMG screening annually and every two to three years, respectively, by the Cancer Expert Working Group. For the overall female population at moderate risk, breast screening was not advised.

hong kong breast cancer therapeutics market

Market Dynamics

Market Growth Drivers

The growing incidence of breast cancer and technical developments are two important market drivers in Hong Kong. The Hong Kong government's efforts in healthcare and cancer research are expected to lead to an increase in the market for breast cancer therapeutics.

Market Restraints

Some of the biggest obstacles to market growth in Hong Kong include a lack of access to newer medicines and high treatment costs. The development of the breast cancer therapeutics market in Hong Kong can potentially be hampered by inadequate healthcare infrastructure and reimbursement regulations.

Competitive Landscape

Key Players

Shanghai Fosun Pharmaceutical (HK)
Sino Biopharmaceutical (HK)
Lee's Pharmaceutical Holdings Ltd (HK)
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Halozyme, Inc.
Merck & Co., Inc.

Healthcare Policies and Regulatory Landscape

The public healthcare system in Hong Kong offers thorough and easily accessible breast cancer treatment. Through the Hospital Authority (HA) and the Department of Health, the government offers financial support for breast cancer screenings, diagnoses, and treatments. There are numerous non-profit organizations that offer assistance and knowledge to people with breast cancer and their families. The Hong Kong Cancer Fund also has a breast cancer support facility that provides a variety of services, such as counseling and rehabilitation. Through the HA's Means-tested Financial Assistance Scheme, patients may also qualify for financial aid.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.